{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:51:25Z","timestamp":1768733485827,"version":"3.49.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.transproceed.2021.09.019","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T22:48:58Z","timestamp":1636843738000},"page":"3056-3064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mammalian Target of Rapamycin Inhibitors Vs Calcineurin Inhibitors in Chronic Graft Rejection After Lung Transplantation: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1016","volume":"53","author":[{"given":"Andressa Rodrigues","family":"de Souza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thulssa Auxiliadora Gomes Medeiros","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-7661","authenticated-orcid":false,"given":"Camila Bomfim","family":"Von Jakitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana L\u00facia Gargione Galv\u00e3o","family":"de Sant'Anna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Carlos Marchiori","family":"de Claudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Nelson Rodrigues","family":"Branco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemeire Simone Dellacrode","family":"Giovanazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1270-8618","authenticated-orcid":false,"given":"Nelson Americo Hossne","family":"Junior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walace de Souza","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suelen Alves Creste Martins","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2743-2949","authenticated-orcid":false,"given":"Puri","family":"Girones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-7663","authenticated-orcid":false,"given":"Regimar Carla","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2021.09.019_bib0001","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart\u2013lung transplantation Report\u20142019; Focus theme: Donor and recipient size match","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.healun.2008.07.018","article-title":"Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart\/lung transplantation report\u20142008","volume":"27","author":"Christie","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107501","article-title":"Real life experience with mTOR-inhibitors after lung transplantation","volume":"94","author":"Bos","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/ijot.ijot_98_20","article-title":"Immunosuppression in lung transplantation: changing perspectives","volume":"15","author":"Shah","year":"2021","journal-title":"Indian J Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0005","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1097\/TP.0000000000001432","article-title":"Recent advances in mammalian target of rapamycin inhibitor use in heart and lung transplantation","volume":"100","author":"Fine","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0006","first-page":"5","article-title":"Individualizing immunosuppression in lung transplantation","volume":"2018","author":"McDermott","year":"2018","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0007","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.transproceed.2011.06.028","article-title":"A retrospective 12-month study of conversion to everolimus in lung transplant recipients","volume":"43","author":"Roman","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0008","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.transproceed.2010.12.055","article-title":"Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study","volume":"43","author":"Fuchs","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0009","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.healun.2010.01.005","article-title":"Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation","volume":"29","author":"Gude","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0010","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.transproceed.2006.08.105","article-title":"Initial single-center experience with sirolimus after lung transplantation","volume":"38","author":"Lischke","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0011","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1053-2498(01)00421-1","article-title":"Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment","volume":"21","author":"Snell","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0013","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions 5.1.0. The Cochrane Collaboration, <http:\/\/www.cochrane-handbook.org>; 2011 [accessed 10.07.21]."},{"key":"10.1016\/j.transproceed.2021.09.019_bib0014","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0016","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1590\/S0104-11692006000100017","article-title":"Perioperative prevention of skin injury: an integrative literature review [in Portuguese]","volume":"14","author":"Ursi","year":"2006","journal-title":"Rev Lat Am Enfermagem"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0017","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1523-1755.2005.00224.x","article-title":"Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study","volume":"67","author":"Shitrit","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0018","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/TP.0b013e3181cbac2d","article-title":"Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial","volume":"89","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0019","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/TP.0b013e3181fd01b7","article-title":"Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial","volume":"90","author":"Gullestad","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.healun.2011.12.010","article-title":"Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate","volume":"31","author":"Arora","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0021","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/tri.12783","article-title":"Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial","volume":"29","author":"Gullestad","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0022","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1111\/ajt.15251","article-title":"A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation","volume":"19","author":"Gottlieb","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0023","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1111\/ajt.13835","article-title":"Everolimus versus mycophenolate mofetil de novo after lung transplantation: a prospective, randomized, open-label trial","volume":"16","author":"Strueber","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0024","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.healun.2012.01.002","article-title":"Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study","volume":"31","author":"Potena","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.201005-0775OC","article-title":"Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation","volume":"183","author":"Bhorade","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0026","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.healun.2007.07.027","article-title":"A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation","volume":"26","author":"Hachem","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0027","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.healun.2005.12.001","article-title":"Everolimus in pulmonary transplantation: pharmacokinetics and exposure\u2013response relationships","volume":"25","author":"Kovarik","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0028","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-6143.2005.01134.x","article-title":"Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial","volume":"6","author":"Snell","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0029","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","article-title":"Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis","volume":"265","author":"Jennings","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0030","first-page":"1940","article-title":"Recovery of chronic renal impairment with sirolimus after lung transplantation","volume":"78","author":"Venuta","year":"2004","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0031","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.healun.2009.03.010","article-title":"Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease","volume":"28","author":"Stephany","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0032","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.tp.0000195781.02268.5e","article-title":"Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation","volume":"81","author":"Groetzner","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trre.2012.11.001","article-title":"Recommendations on the use of everolimus in lung transplantation","volume":"27","author":"de Pablo","year":"2013","journal-title":"Transplant Rev"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0034","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.healun.2004.01.014","article-title":"Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus","volume":"24","author":"Villanueva","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1053-2498(02)00550-8","article-title":"Early experience with sirolimus in lung transplant recipients with chronic allograft rejection","volume":"22","author":"Cahill","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0036","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0022-5223(99)70291-6","article-title":"Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection","volume":"117","author":"Longoria","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0037","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.transproceed.2004.01.015","article-title":"The evolving experience using everolimus in clinical transplantation","volume":"36","author":"Formica","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0038","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.transproceed.2009.12.004","article-title":"Everolimus in lung transplantation in Chile","volume":"42","author":"Parada","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0039","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.healun.2014.06.001","article-title":"Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation","volume":"34","author":"Glanville","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0040","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/j.transproceed.2010.12.059","article-title":"Increased incidence of acute graft rejection on calcineurin inhibitor\u2013free immunosuppression after heart transplantation","volume":"43","author":"Celik","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0041","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/S0041-1345(01)02369-7","article-title":"The role of Certican (everolimus, rad) in the many pathways of chronic rejection","volume":"33","author":"Nashan","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0042","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/152692480401400202","article-title":"Chronic allograft nephropathy: pathogenesis and management of an important posttransplant complication","volume":"14","author":"Aull","year":"2004","journal-title":"Prog Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0043","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/00007890-200010150-00018","article-title":"Increased impact of acute rejection on chronic allograft failure in recent era","volume":"70","author":"Meier-Kriesche","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0044","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","article-title":"Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment\u2015A consensus report from the Pulmonary Council of the ISHLT","volume":"38","author":"Verleden","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0045","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.21037\/jtd.2017.07.81","article-title":"Chronic lung allograft dysfunction phenotypes and treatment","volume":"9","author":"Verleden","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0046","doi-asserted-by":"crossref","first-page":"e13038","DOI":"10.1111\/ctr.13038","article-title":"Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up: Results of a randomized controlled trial (SCHEDULE)","volume":"31","author":"Relbo Authen","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0047","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/TP.0b013e3181c42b95","article-title":"Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study","volume":"89","author":"Potena","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0048","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2013.11.036","article-title":"Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?","volume":"171","author":"Gonzalez-Vilchez","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0049","article-title":"Avalia\u00e7\u00e3o dos imunossupressores micofenolatomofetil, sirolimo e tacrolimo usados no tratamento de manuten\u00e7\u00e3o de transplantes renais realizados no Sistema \u00danico de Sa\u00fade do Brasil entre 2000 e 2006 [in Portuguese]","volume":"127","author":"Duraes","year":"2013"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0050","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/j.1600-6143.2012.04131.x","article-title":"Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency","volume":"12","author":"Zuckermann","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0051","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0052","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1016\/j.transproceed.2010.05.064","article-title":"Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment","volume":"42","author":"de la Morena","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2021.09.019_bib0053","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/TP.0b013e3181cbe024","article-title":"Predictors of renal dysfunction at 1 year in heart transplant patients","volume":"89","author":"Navarro-Manch\u00f3n","year":"2010","journal-title":"Transplantation"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521007004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134521007004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:42:10Z","timestamp":1758577330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134521007004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0041134521007004"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.09.019","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mammalian Target of Rapamycin Inhibitors Vs Calcineurin Inhibitors in Chronic Graft Rejection After Lung Transplantation: A Systematic Review and Meta\u2010Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2021.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}